https://www.cancertherapyadvisor.com/home/news/conference-coverage/asco-gi-2023/colorectal-cancer-botensilimab-balstilimab-yields-durable-response-treatment/
0
0
1/22/23 at 9:00am
Organization
Cancertherapyadvisor.com
33 words
0
Comments
Combination botensilimab and balstilimab elicits durable responses in refractory, metastatic, microsatellite-stable colorectal cancer, a phase 1 trial suggests.
You are the first to view
Create an account
or login to join the discussion